These findings are in line with earlier studies showing in NASH rodent models that sitagliptin, another DPP-4 inhibitor, inhibited liver fibrosis by suppressing steatosis and oxidative stress [37,38,39]. Here, DPP4 is linked to metabolic dysfunction-associated steatohepatitis.